A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.

Sponsor
Anaveon AG
Study ID
NCT04855929
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ANV419 — DRUG
    ANV419 administered by intravenous (IV) infusion
  • Ipilimumab — DRUG
    Ipilimumab administered by intravenous (IV) infusion

Study Details

The purpose of this study is to test the safety and efficacy of ANV419 (single agent) and in combination with ipilimumab in patients with relapsed/refractory advanced solid tumors.

Key Dates

Start date
May 25, 2021
Status verified
Nov 2024
Primary completion
Jul 18, 2024
Completion
Jul 18, 2024

Study Design

Enrollment
55 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: ANV419 single agent
  • Experimental: Ipilimumab + ANV419

Primary Outcome Measure

Monotherapy: Number of Dose-Limiting Toxicities (DLTs) [ Time Frame: Day 1 to Day 14 ]

Related Studies